



your  
**partner**  
that  
**cares**

## **VALUE ADDED MEDICINES**

Patient-Centric Solutions to  
Empower your Portfolio



# Bluepharma

## About Us

Bluepharma's dynamic and technology-driven culture aims to create differentiated solutions that transform patient care and address unmet medical needs.

With a history of successful co-development projects and a wide array of technological platforms, we are the ideal partner to develop value-added medicines.

over  
**120**  
R&D Projects

over  
**40**  
International Territories

over  
**15%**  
R&D Investment

over  
**50**  
Scientific Articles

over  
**40**  
PhDs

over  
**30**  
Patents

## Our Differentiated Solutions

### OROMUCOSAL DELIVERY

- Buccal Sprays  
**BluEase™**
- Oral Thin Films  
**BlueOS®**
- ODTs & Buccal Tablets

### ORAL SOLID DOSAGE

- Fixed Dose Combinations  
(e.g. Multilayer tablets)
- Improved Solid Dosage Forms (e.g. HME)

### COMPLEX STERILES

- Lipid-Based Formulations
- Polymer-Based Formulations



**scan me**  
With eyes set  
on the future



**Technologies  
& Platforms**



# Oromucosal Delivery

Versatile Platforms designed to **address patient's everyday challenges.**

**BlueOS®** and **BluEase™** are Bluepharma's proprietary technologies, with IP rights granted in the major worldwide markets.



### IMPROVED CONVENIENCE

- Easily taken "on-the-go" and without water.
- Dose flexibility in titration procedures.



### IMPROVED SAFETY

- Able to target special patient populations.
- Potential for bioavailability enhancement.
- Potential to decrease gastrointestinal side-effects.



### VERSATILITY

- Ability to modulate the onset of action.
- Flavour adjustment to target population.
- Can be used for transmucosal delivery or swallowed.
- Appropriate for local or systemic delivery.



**Applicable for emergency use as well as treatment of chronic conditions:**


INDICATION	VALUE PROPOSITION	Prototype Development	Clinical POC	Scale-up & Validation	Clinical Development	Available/ Commercial
Multiple Sclerosis	Oral thin film that improves the convenience of administration in pediatric and dysphagic patients.					
Oral Mucositis	<ul style="list-style-type: none"><li>• Spray that adheres to the buccal mucosa and creates a protective barrier.</li><li>• Non-opioid pain management.</li></ul>					
Migraine	<ul style="list-style-type: none"><li>• ODT to allow a discrete administration.</li><li>• Can be taken "on-the-go" and without water.</li></ul>					

# Oral Solid Dosage


## Fixed Dose Combinations

Fixed Dose Combinations (FDC) aim to reduce the pill burden in polymedicated patients, improving treatment compliance and, therefore, increasing efficacy.

Our in-house technologies allow us to combine incompatible molecules in the same pharmaceutical dosage form.



## Improved Solid Dosage Forms



## Other Available Technologies

- Micro-Tablets.
- Capsules, Micro-Tablets, or Pellets inside Capsules.
- Hot Melt Extrusion.



Comprehensive Solutions backed by  
**End-to-End Analytical Expertise**  
and **Advanced Techniques.**



# Complex Steriles

## Lipid-Based Formulations

Bluepharma has more than 25 years of accumulated experience in lipid-based formulations. Discover our targeted liposome products that deliver drugs directly to target cells, maximizing efficacy and minimizing side effects.




## Polymer-Based Formulations

Bluepharma is developing an innovative Long Acting Injectable (LAI) platform comprised of *in situ* forming hydrogel with embedded microparticles. We performed POC trials that revealed significant advantages compared to currently marketed polymer-based therapies.


VALUE PROPOSITION

- Tunable drug release profile.
- Minimal to inexistnt burst release.
- High loading capacity.



## Other Available Polymeric and Lipid-Based Platforms

- Solid Sterile Implants & Inserts.
- Lipid Nanoparticles (LNPs).
- Polymeric Nanoparticles (PNPs).



# Why Bluepharma?



Versatile technology portfolio with a wide range of applications.



Integrated approach, from R&D to the Market.



Flexible business models, tailored to partner expectations.



Vast contact network.



Global quality certifications and regulatory expertise.

Bluepharma's facilities are certified/approved by:

- Infarmed/EMA (European Union)
- US FDA (2009, 2012, 2014, 2016, 2019)
- SFDA (Kingdom of Saudi Arabia)
- MFDS (South Korea)
- MSHP (Ivory Coast)
- MOH (Libya)
- TMMDA (Turkey)

We are registered in Iraq, Taiwan, Jordan, UAE, Kurdistan, Vietnam, Bahrain and Oman.

Create **value** through **Innovation**. How? Contact us!



*scan me*  
Product Portfolio

For business inquiries:  
**vam@bluepharma.pt**

Coimbra · PORTUGAL  
Tel. +351 239 800 300

[www.bluepharmagroup.com](http://www.bluepharmagroup.com)